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INTRODUCTION
Galectins are members of the animal lectins, a
family of carbohydrate-binding proteins character-
ized by their affinity for β -galactoside and by a con-
served sequence of the carbohydrate recognition
domain. Fourteen members of the galectin family
have been identified to date (1-3). Galectin-3 is a
31-kDa gene product that serves as an intracellu-
lar and extracellular lectin and that is thought to in-
teract with glycoproteins located on the cell surface
matrix (1-2). Galectin-3 is broadly expressed in
numerous tumors, including renal cell carcinoma
(RCC), and has been shown to be involved in nu-
merous cellular processes including growth, prolif-
eration, differentiation, adhesion, cell-cycle progres-
sion, angiogenesis and apoptosis, mainly through its
binding to glycoproteins (4-11). Clinical evidence
has shown that the expression of galectin-3 is also
associated with carcinogenesis and malignant po-
tential in the head and neck, thyroid, breast, gastro-
intestinal tract, pancreas, uterus and bladder (12-18).
Recent array studies have revealed that galectin-3
is up-regulated in conventional RCC (19-20). In the
present study, we investigated the expression of
galectin-3 in clear cell RCC (CC-RCC) and revealed
significantly higher galectin-3 expression in CC-
RCC than in renal parenchyma obtained from the
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same patients. We also found that the expression
level of galectin-3 in CC-RCC with distant metas-
tasis was significantly higher than that in CC-RCC
without distant metastasis.
MATERIALS AND METHODS
Cell Culture
The human kidney cancer cell lines Caki-1, Caki-
2, A704, ACHN and KPK-1 were obtained from
ATCC (Manassas, VA, USA). The cells were main-
tained in RPMI 1640 containing 2 mM glutamine,
penicillin-streptomycin (Life Technologies, Inc.,
Grand Island, NY, USA) and 10% fetal bovine serum
(FBS) in 5% CO2 at 37.
Patient Characteristics
We studied CC-RCC samples obtained from 66
patients with CC-RCC who underwent nephrec-
tomy between 1996 and 2006 at the Department of
Urology, the University of Tokushima, Japan. In-
formed consent was obtained from all patients prior
to inclusion in this study, and the Research Ethics
Committee of the University of Tokushima Faculty of
Medicine approved the study. Of the 66 patients, 41
were male and 25 were female. The patients had a
mean age of 61.9 years (range : 40 to 81 years). Any
patients with a renal tumor that was histologically
different from CC-RCC were excluded from the
study. None of the patients had received neoadju-
vant chemotherapy or interferon and/or interleukin-
2 (IL-2) immunotherapy. Tumors were staged ac-
cording to the TNM staging classification of the In-
ternational Union Against Cancer (21). Staging pro-
cedures included physical examination, chest radi-
ography, ultrasonography and computerized to-
mography. If caval invasion was suspected, magnetic
resonance scanning was performed. Patients with
elevated serum alkaline phosphate levels or skele-
tal symptoms were assessed using bone scintigra-
phy and radiography. As presented in Table 1, the
patients were staged as follows : 27 in stage I, 21
in stage II, 4 in stage III and 14 in stage IV. Four-
teen patients had tumors with distant metastasis in-
cluding 13 with lung metastasis, 3 with bone me-
tastasis, 1 with liver metastasis, 1 with pancreatic
metastasis, 1 with adrenal metastasis and 1 with
lymph node metastasis. Five patients demonstrated
multiple organ metastasis. Tumor nuclear grading
was performed according to the 1997 TNM grading
system (22). The grade distribution was as follows :
18 in grade 1, 32 in grade 2 and 16 in grade 3.
Follow-up examination ranged from 6.9 to 129.0
months (median : 38.6 months).
Western Blot Analysis
Western blot analyses were performed using the
enhanced chemiluminescence (ECL) detection sys-
tem (GE Healthcare, Piscataway, NJ, USA) as de-
scribed previously (9-10). Aliquots of protein (20
μg) were separated on a 12.5% SDS-PAGE gel us-
ing the method of Laemmli and transferred to a
polyvinylidene difluoride membrane. The membrane
was blocked with 5% non-fat dry milk in phosphate
buffered saline (PBS)-0.1% Tween 20 at 4over-
night. The membrane was then incubated with pri-
mary antibody for 1 hour. Immunoreactivity was de-
tected by sequential incubation with horseradish
peroxidase (HRP)-conjugated secondary antibody
and ECL reagents. Antibodies were obtained from
the following sources : anti-galectin-3 monoclonal
antibody (TIB166 ; American Type Culture Collec-
tion) ; anti-glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) antibody (Sigma-Aldrich, St. Louis,
MO, USA), horseradish peroxidase (HRP)-conju-
gated anti-mouse antibody and anti-rat antibody (In-
vitrogen, Carlsbad, CA, USA).
Table 1 Clear cell renal cell carcinoma patient characteristics
Characteristics No. of patients
Age
40-81 years (mean, 61.9 years)
Sex
Male 41
Female 25
Clinical stage
I 27
II 21
III 4
IV 14
Histologic grade (G)
G1 18
G2 32
G3 16
Metastasis (M)
M0 52
M1 14
Follow-up period
6.9-129.0 months (median, 38.6 months)
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Relative Semi-Quantitative RT-PCR
Expression of galectin-3 in the 66 CC-RCC tis-
sues and normal parenchyma obtained from patients
with CC-RCC were measured using real-time PCR
as described previously (22). Tissue samples for
RNA extraction were immediately submerged in
RNA Later, incubated at 4overnight and stored
at -80until required. Total RNA was then ex-
tracted using the RNeasy kit (Qiagen, Inc., Valencia,
CA) following the manufacturer’s instructions. To
avoid DNA contamination, RNA was digested with
RNase-free DNase (Qiagen) as recommended by
the supplier. Total RNA was quantified using a UV
spectrophotometer, and the quality and integrity
was assessed on a 1.5% agarose gel. Total RNA (1
μg) was then reverse transcribed using the First-
Standard cDNA Synthesis Kit (GE Healthcare, Pis-
cataway, NJ, USA) according to the protocol of the
manufacturer. To examine the expression levels of
galectin-3 and the housekeeping gene GAPDH, real-
time quantitative PCR was performed using the
Roche LightCycler System (Roche, Diagnostic
GmbH, Mannheim, Germany) and SYBR Green I
dye. The sense and antisense primer sequences
for galectin-3 have been described previously (22).
For GAPDH, the PCR reaction was carried out us-
ing the LightCyclerTM-Primer Set ready-to-use am-
plification primer mix for RT-PCR. For each sam-
ple, the amount of target and endogenous control
(GAPDH) were determined using a calibration
curve. The amount of the target was calculated as
a ratio of the number of target (T) gene copies to
the housekeeping (H) gene copies.
Immunohistochemical Staining
Tissue samples obtained from patients with CC-
RCC were frozen in OCT compound (Tissue-Tek,
Sakura Fine Chemical, Tokyo, Japan) and stored
at -80as described previously (22). Serial 10-μm
sections were cut using a cryotome (CM-501, Tis-
sue-Tek) and mounted on glass slides. Sections
were then dried and fixed with 4% paraformaldehyde
in 0.1 M PBS for 15-30 min at 20. The sections
were incubated with 1% bovine serum albumin
(BSA) in PBS for 1 h at 20and then with rat
monoclonal antibody against galectin-3 (1 : 500 ;
TIB166 ; American Type Culture Collection) for 2-
3 hours at 20. After rinsing in PBS, the sections
were further incubated with fluorescein isothiocy-
anate (FITC)-labeled anti-rat IgG (1 : 200 ; Jackson
Immunoresearch Laboratories Inc., West Grove,
PA, USA) in 1% BSA in PBS for 2 h at 20. 4’, 6-
diamidino-2-phenylindole (DAPI, Kierkegaard and
Perry Laboratories, Gaithersburg, MD, USA) was
then applied for 15 min to stain the nuclei. After this,
sections were mounted with Vectashield (Vector
Laboratories, INC, Burlingame, CA, USA) and ex-
amined using a confocal laser-scanning light micro-
scope (Bio-Rad Radiance 2000, Bio-Rad Laborato-
ries, Hercules, CA, USA).
Statistical Analysis
Statistical analyses were performed using StatView
5.0 software (Abacus Concepts, Berkeley, CA, USA).
Real-time PCR data is presented as the meanSE
for each of the clinicopathological variables such as
stage and grade, and the statistical significance was
determined using Student’s t test and differences
were considered statistically significant at p0.05.
The Kaplan-Meier method and log-rank test were
used to compare group differences in cause-specific
survival. Values are presented as the mean (SEM)
and differences were considered significant at p
0.05.
RESULTS
The expression of galectin-3 in kidney cancer cell
lines and CC-RCC tissue
Overexpression of galectin-3 was observed in all
of the human RCC cell lines investigated, including
Caki-1, Caki-2, A704, ACHN and KPK-1 (Fig. 1).
Fig. 1 Expression of galectin-3 in the renal cell carcinoma
(RCC) cell lines Caki-1 Caki-2, A704, ACHN and KPK-1 by west-
ern blot analysis with 20 μg of protein loaded into each lane. The
expression of anti -glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was measured as an internal control. Overexpression
of galectin-3 (31 kDa) was detected in all human RCC cell lines
investigated.
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The expression level of galectin-3 in CC-RCC ob-
tained following nephrectomy was significantly
higher than that in the normal renal parenchyma
obtained from the same kidney (n=66, p=0.039,
Fig. 2A). The expression level of galectin-3 in CC-
RCC with distant metastasis (M1) was significantly
higher than that in CC-RCC without distant metas-
tasis (M0, p=0.045, Fig. 2B). There was no signifi-
cant correlation between galectin-3 expression and
T category, N category, presence of tumor throm-
bus, number of metastases and metastatic organs
(data not shown). There was also no difference in
galectin-3 expression between CC-RCC with lung
metastasis and CC-RCC with multiple organ metas-
tasis (data not shown). Though the expression level
of galectin-3 in grade 3 CC-RCC tended to be
higher than that in grade 1 CC-RCC (p=0.098),
there was no significant difference in expression
levels of galectin-3 in each nuclear grade (G1 vs G2,
p=0.43 and G2 vs G3, p=0.12, Fig. 2C).
To validate the RT-PCR data, we stained CC-RCC
tissue samples with a galectin-3 antibody using im-
munofluorescence. We detected weak expression in
the organ-confined low-grade (T1N0M0/G1) CC-
RCC samples (Fig. 3A, 3C) and intense expression
in advanced disease and high -grade (T3N0M1/
G2G3) CC-RCC samples (Fig. 3B, 3D). To deter-
mine whether galectin-3 expression was correlated
with patient outcome, we divided the CC-RCC sam-
ples into subgroups of high and low expression us-
ing a variety of cutoff values. There was no signifi-
cant difference between galectin-3 expression and
clinical outcome (data not shown).
Fig. 3 Microscopic analysis of the CC-RCC samples. A and
C, sections obtained from a T1N0M0/G1 CC-RCC sample and
B and D, sections obtained from a T3aN0M1/G2G3 CC-RCC
sample. Hematoxylin and eosin were used to stain the sections
presented in A and B. Representative images of the immunofluo-
rescence staining of CC-RCC tissues using monoclonal anti -
galectin-3 antibody are presented in C and D. We observed weak
expression of galectin-3 (green) in the T1N0M0/G1 CC-RCC
sample (C) and intense expression in the T3aN0M1/G2G3
CC-RCC sample (D). 4’, 6 -diamidino-2-phenylindole (DAPI) was
used to stain the nuclei (blue). Immunohistochemical analysis
of galectin-3 expression revealed both cell surface and cytoplas-
mic staining in the RCC specimens. Scale bar=100 μm.
A
B
C
Fig. 2 Galectin-3 expression in normal parenchyma and clear
cell renal cell carcinoma (CC-RCC) tissue samples obtained fol-
lowing nephrectomy. A, CC-RCC vs normal parenchyma. A sig-
nificantly higher mean ratio of galectin-3 to GAPDH expression
in the CC-RCC tumors was observed than in the normal kidney
parenchyma tissues (p=0.039). B, M0 vs M1. Patients with M1
demonstrated a significantly higher galectin-3 expression level
than patients with M0 (p=0.045). C, The various histological
grades of galectin-3 expression. Patients with grade 3 (G3) CC-
RCC tended to be higher than those in grade 1 (G1) CC-RCC
(p=0.098).
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DISCUSSION
Galectin-3 is a member of the galectin gene fam-
ily and is expressed at elevated levels in a variety
of cancers (23). In renal cell carcinoma, it has been
shown that galectin-3 expression was significantly
higher in conventional CC-RCCs and chromophobe
RCCs (19, 20). Galectin-3 expression has also been
associated with tumor progression and metastasis
through its role in the regulation of cellular growth,
adhesion, proliferation, cell-cycle progression, an-
giogenesis and apoptosis (4-11). Galectin-3 is lo-
calized not only in intracellular spaces such as the
cytoplasm and the nucleus, but also in extracellular
spaces such as the cell surface and the extracellu-
lar matrix (24). We have reported previously that
secreted extracellular galectin-3 induced apoptosis
of T-cells, suggesting that galectin-3 may be impor-
tant for the immune escape mechanisms operating
during tumor progression (10). Therefore, galectin-
3 may play an important role in CC-RCC progres-
sion as CC-RCC is sensitive to immune therapy
treatments including interferon and IL-2 admini-
stration.
In the present study, we evaluated galectin-3 ex-
pression in both RCC cell lines and surgical speci-
mens of CC-RCC using real-time quantitative RT-
PCR and analyzed its relationships with the clini-
copathological factors of CC-RCC. We revealed that
galectin-3 was overexpressed in adenocarcinoma
(A704, ACHN and KPK-1) and CC- (Caki 1, Caki 2)
RCC cell lines. In addition, galectin-3 expression
was up-regulated in CC-RCC compared to that in
normal kidney tissues, suggesting that the up-regu-
lation of galectin-3 is an early event in CC-RCC de-
velopment. The expression level of galectin-3 was
also higher in advanced disease (M1) than in organ-
confined (M0) tumors, suggesting that galectin-3
might be associated with RCC metastasis. Results
from the confocal laser microscopy examination con-
firmed intense expression of galectin-3 in advanced
tumors compared to organ-confined tumors. These
results were also supported by our RT-PCR results.
We found that there was no significant correlation
in the survival rate between high galectin-3-express-
ing CC-RCC and low galectin-3-expressing CC-
RCC. Taken together, these findings demonstrate
that the expression of galectin-3 correlates with the
presence of metastasis. If galectin-3 secreted from
RCC induces apoptosis in T cells as we have previ-
ously shown (10), this induction of T-cell apoptosis
by secreted galectin-3 potentially provides novel
insight into the immune escape mechanisms un-
derlying CC-RCC. Further examination is required
to fully investigate these hypotheses.
CONCLUSIONS
Galectin-3 is highly expressed in kidney cancer
cell lines and CC-RCC and especially in CC-RCC
with distant metastasis. We found that there was
no positive correlation between galectin-3 expres-
sion and prognosis in CC-RCC. These results sug-
gest that galectin-3 serves as a target molecule for
predicting metastasis of RCC. Further, more de-
tailed study may lead to the elucidation of galectin-
3-regulated microenvironments in CC-RCC.
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